Avid Bioservices Inc (CDMO)

[senrex]

Jazz - thank you for the response. I've always thought that Bavi for cancer would be the big winner, and I was surprised (and initially worried) that management placed such a high emphasis on HCV first (with viruses MANY more things can go wrong). Is it safe to assume that this was primarily for strategic reasons: i.e. licensing Bavi to a large pharma (mostly because it's a more complicated trick to master and that pharma can apply the big $ necessary to answer questions like optimal dosing)? Then, with the licensing $, PPHM can proceed to develop Bavi for cancer on its own?

TIA

Sean